1. Home
  2. ULY vs VIVS Comparison

ULY vs VIVS Comparison

Compare ULY & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ULY
  • VIVS
  • Stock Information
  • Founded
  • ULY 2013
  • VIVS 2007
  • Country
  • ULY United States
  • VIVS United States
  • Employees
  • ULY N/A
  • VIVS 13
  • Industry
  • ULY
  • VIVS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ULY
  • VIVS Health Care
  • Exchange
  • ULY Nasdaq
  • VIVS Nasdaq
  • Market Cap
  • ULY 5.8M
  • VIVS 8.1M
  • IPO Year
  • ULY N/A
  • VIVS N/A
  • Fundamental
  • Price
  • ULY $3.45
  • VIVS N/A
  • Analyst Decision
  • ULY Strong Buy
  • VIVS
  • Analyst Count
  • ULY 2
  • VIVS 0
  • Target Price
  • ULY $11.50
  • VIVS N/A
  • AVG Volume (30 Days)
  • ULY 983.2K
  • VIVS 135.1K
  • Earning Date
  • ULY 11-11-2025
  • VIVS 11-07-2025
  • Dividend Yield
  • ULY N/A
  • VIVS N/A
  • EPS Growth
  • ULY N/A
  • VIVS N/A
  • EPS
  • ULY N/A
  • VIVS N/A
  • Revenue
  • ULY $131,235,000.00
  • VIVS $142,000.00
  • Revenue This Year
  • ULY N/A
  • VIVS $42.38
  • Revenue Next Year
  • ULY $20.23
  • VIVS $15.42
  • P/E Ratio
  • ULY N/A
  • VIVS N/A
  • Revenue Growth
  • ULY N/A
  • VIVS 94.52
  • 52 Week Low
  • ULY $2.75
  • VIVS $1.41
  • 52 Week High
  • ULY $17.99
  • VIVS $21.96
  • Technical
  • Relative Strength Index (RSI)
  • ULY 43.39
  • VIVS 51.52
  • Support Level
  • ULY $2.75
  • VIVS $2.90
  • Resistance Level
  • ULY $5.60
  • VIVS $3.48
  • Average True Range (ATR)
  • ULY 0.45
  • VIVS 0.33
  • MACD
  • ULY 0.03
  • VIVS -0.09
  • Stochastic Oscillator
  • ULY 23.50
  • VIVS 23.02

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: